logo

For the Inventor, By the Inventor

Abingdon, United Kingdom

Psioxus Therapeutics Limited

Calculating rank
USPTO Granted Patents = 22

% Expired Patents = 13.6



Trademarks = 1

Forward Citations = 74

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Brian Robert Champion (10 out of 24 patents)

silverMedal Alice Claire Noel Brown (8 out of 11 patents)

bronzeMedal Terry Hermiston (7 out of 32 patents)

4.  Irene Kuhn (6 out of 7 patents)

5.  Paul Harden (5 out of 6 patents)

6.  Kerry David Fisher (4 out of 10 patents)

7.  Alice Claire Noel Bromley (3 out of 6 patents)

8.  Tamara Nicolson (3 out of 9 patents)

9.  John William Beadle (2 out of 2 patents)

10.  Stefan Anker (1 out of 16 patents)

11.  Christine Wilkinson Blanc (1 out of 2 patents)

12.  Matthieu Besneux (1 out of 1 patent)

13.  Jochen Springer (1 out of 9 patents)

14.  Benjamin Guy Davis (1 out of 11 patents)

15.  Peter Kretschmer (1 out of 4 patents)


22 patents:

1. 11439678 - Oncolytic adenoviruses armed with heterologous genes (2022-09-13),
2. 11173186 - Dosing regime and formulations for type B adenovirus (2021-11-16),
3. 11155622 - Virus encoding an anti-TCR-complex antibody or fragment (2021-10-26),
4. 11142580 - Oncolytic virus and method (2021-10-12),
5. 11000559 - Oncolytic adenovirus encoding a B7 protein (2021-05-11),
6. 10849945 - Oncolytic adenovirus encoding a B7 protein or active fragment (2020-12-01),
7. 10548929 - Oncolytic adenovirus encoding a therapeutic protein or active fragment (2020-02-04),
8. 10472648 - Method of making adenovirus and corresponding plasmids (2019-11-12),
9. 10322152 - Oncolytic adenovirus encoding a B7 protein (2019-06-18),
10. 10124028 - Oncolytic adenovirus encoding a B7 protein or active fragment (2018-11-13),
11. 10034905 - Group B adenovirus modified in the E4orf4 region (2018-07-31),
12. 9987314 - Oncolytic adenoviruses armed with heterologous genes (2018-06-05),
13. 9234185 - Chimeric adenoviruses for use in cancer treatment (2016-01-12),
14. 9115337 - Chimeric adenoviruses for use in cancer treatment (2015-08-25),
15. 9034344 - Chimeric adenoviruses for use in cancer treatment (2015-05-19),
Company Overview
Psioxus Therapeutics Limited is a biotechnology company based in Abingdon, UK, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the design and manufacture of oncolytic virus therapies, leveraging its proprietary platform to create targeted treatments that harness the immune system's ability to fight tumors. Psioxus is committed to advancing its research in viral therapeutics, aiming to improve patient outcomes through cutting-edge scientific advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

22 Patents

#11 in Abingdon

#817 in United Kingdom

#28,870 in the World

Abingdon, GB
Abingdon, United Kingdom

Psioxus Therapeutics Limited

Forward Citations = 74

20 inventors:

goldMedal Brian Robert Champion (10 out of 24 patents)

silverMedal Alice Claire Noel Brown (8 out of 11 patents)

bronzeMedal Terry Hermiston (7 out of 32 patents)

4.  Irene Kuhn (6 out of 7 patents)

5.  Paul Harden (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Psioxus Therapeutics Limited. Retrieved from https://idiyas.com/company/psioxus-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…